OKYO Pharma Limited (OKYO)
| Market Cap | 48.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.27M |
| Shares Out | 21.77M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150,018 |
| Open | 2.58 |
| Previous Close | 2.65 |
| Day's Range | 2.10 - 2.63 |
| 52-Week Range | 2.10 - 6.11 |
| Beta | 0.27 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About OKYO
OKYO Pharma is a preclinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. Our research program is focused on a novel G Protein-Coupled Receptor, which we believe plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical pr...
Financial Performance
Financial StatementsNews
OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation
OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases...
OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market an...
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain...
Ocular disease biotech OKYO Pharma files for a $12 million US IPO
OKYO Pharma, a preclinical biotech developing a lipidated chemerin analog for dry eye disease, filed on Friday with the SEC to raise up to $12 million in an initial public offering.
OKYO Pharma IPO Registration Document (F-1)
OKYO Pharma has filed to go public with an IPO on the NASDAQ.
OKYO Pharma announces Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat D...
OK-101 First-in-Human Trial planned as Phase 2 Trial incorporating Primary Efficacy Endpoints covering Signs and Symptoms of Dry Eye Disease